MUFG Americas Holdings Corp trimmed its holdings in Eli Lilly and Co (NYSE:LLY) by 0.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 164,972 shares of the company’s stock after selling 1,254 shares during the quarter. MUFG Americas Holdings Corp’s holdings in Eli Lilly and were worth $14,112,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also made changes to their positions in the company. Pathstone Family Office LLC increased its holdings in Eli Lilly and by 100.0% during the 2nd quarter. Pathstone Family Office LLC now owns 58 shares of the company’s stock worth $4,774,000 after purchasing an additional 29 shares in the last quarter. Vantage Financial Partners Ltd. Inc. bought a new stake in Eli Lilly and during the 2nd quarter worth approximately $494,000. Acrospire Investment Management LLC increased its holdings in Eli Lilly and by 16.7% during the 2nd quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock worth $115,000 after purchasing an additional 200 shares in the last quarter. MPS Loria Financial Planners LLC bought a new stake in Eli Lilly and during the 2nd quarter worth approximately $128,000. Finally, San Francisco Sentry Investment Group CA bought a new stake in Eli Lilly and during the 2nd quarter worth approximately $129,000. 76.31% of the stock is currently owned by institutional investors.
Shares of Eli Lilly and Co (NYSE:LLY) opened at $86.98 on Friday. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 0.66. Eli Lilly and Co has a 12 month low of $74.00 and a 12 month high of $89.09. The stock has a market capitalization of $95,770.00, a PE ratio of 41.42, a P/E/G ratio of 1.62 and a beta of 0.35.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.03 by $0.02. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The business had revenue of $5.66 billion during the quarter, compared to analyst estimates of $5.52 billion. During the same period last year, the business posted $0.88 earnings per share. Eli Lilly and’s quarterly revenue was up 9.0% compared to the same quarter last year. analysts predict that Eli Lilly and Co will post 4.22 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, March 9th. Stockholders of record on Thursday, February 15th will be issued a dividend of $0.5625 per share. This represents a $2.25 annualized dividend and a dividend yield of 2.59%. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.52. The ex-dividend date is Wednesday, February 14th. Eli Lilly and’s dividend payout ratio (DPR) is presently 99.05%.
In other Eli Lilly and news, SVP Alfonso G. Zulueta sold 2,003 shares of Eli Lilly and stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $83.67, for a total value of $167,591.01. Following the completion of the sale, the senior vice president now owns 43,580 shares of the company’s stock, valued at approximately $3,646,338.60. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder Lilly Endowment Inc sold 200,000 shares of Eli Lilly and stock in a transaction that occurred on Wednesday, December 13th. The stock was sold at an average price of $88.20, for a total transaction of $17,640,000.00. Following the completion of the sale, the insider now directly owns 123,084,104 shares of the company’s stock, valued at approximately $10,856,017,972.80. The disclosure for this sale can be found here. Insiders have sold 251,088 shares of company stock valued at $22,041,236 over the last quarter. Company insiders own 0.20% of the company’s stock.
Several equities analysts have recently issued reports on the company. BMO Capital Markets set a $73.00 target price on Eli Lilly and and gave the company a “sell” rating in a report on Tuesday, December 5th. Leerink Swann increased their price objective on Eli Lilly and from $92.00 to $93.00 and gave the company a “market perform” rating in a report on Monday, October 23rd. Credit Suisse Group reissued a “hold” rating on shares of Eli Lilly and in a report on Wednesday, December 13th. Goldman Sachs Group reissued a “buy” rating and set a $95.00 price objective (up from $92.00) on shares of Eli Lilly and in a report on Thursday, October 5th. Finally, Argus upgraded Eli Lilly and from a “hold” rating to a “buy” rating and increased their target price for the stock from $85.52 to $115.00 in a research report on Friday, January 5th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and ten have given a buy rating to the company. Eli Lilly and has a consensus rating of “Hold” and an average target price of $92.14.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.